A PHASE 2/3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND OPEN-LABEL EXTENSION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN IN A PEDIATRIC POPULATION WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

Registry ID

CY 6023

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

CYTOKINETICS, INCORPORATED

Start date

2026-01-02

Last update

2024-10-07

Conditions

• HYPERTROPHIC CARDIOMYOPATHY

Related clinical trials

• A FOLLOW-UP, OPEN-LABEL, RESEARCH EVALUATION OF SUSTAINED TREATMENT WITH AFICAMTEN (CK-3773274) IN HYPERTROPHIC CARDIOMYOPATHY (HCM)
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY TO EVALUATE MAVACAMTEN ADOLESCENTS (AGE 12 YEARS TO < 18 YEARS) WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
• HCMR - NOVEL PREDICTORS OF OUTCOME IN HYPERTROPHIC CARDIOMYOPATHY

View on source registry